Identification of the Effect of Multiple Polymorphisms on the Pharmacokinetics of Simvastatin and Simvastatin Acid Using a Population-Modeling Approach

dbSNP: the NCBI database of genetic variation

Sherry, S. T. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.308 · Cited by 7,502 · see citing works

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial

(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992 · see citing works

Regulation of the mevalonate pathway

Goldstein, J. L., & Brown, M. S. (1990) · Nature · doi:10.1038/343425a0 · Cited by 5,394 · see citing works

<i>SLCO1B1</i> Variants and Statin-Induced Myopathy — A Genomewide Study

(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043 · see citing works

Age‐related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications

Mangoni, A. A., & Jackson, S. H. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.02007.x · Cited by 1,887 · see citing works

Statin-associated myopathy

Thompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463 · see citing works

Ways to Fit a PK Model with Some Data Below the Quantification Limit

Beal, S. L. (2001) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1023/a:1012299115260 · Cited by 1,116 · see citing works

Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake

Niemi, M., Pasanen, M. K., & Neuvonen, P. J. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002857 · Cited by 636 · see citing works

Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

Wang, D., Guo, Y., Wrighton, S. A., Cooke, G., & Sadée, W. (2010) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.28 · Cited by 507 · see citing works

Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment

LEE, E., RYAN, S., Birmingham, B. K., Zalikowski, J. A., March, R. E., Ambrose, H., MOORE, R., Lee, C. G. L., CHEN, Y., & Schneck, D. W. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.013 · Cited by 480 · see citing works

SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

Pasanen, M. K., Neuvonen, M., Neuvonen, P. J., & Niemi, M. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000230416.82349.90 · Cited by 470 · see citing works

SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid

Tornio, A., Vakkilainen, J., Neuvonen, M., Backman, J. T., Neuvonen, P. J., & Niemi, M. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000148 · Cited by 410 · see citing works

Glucuronidation of Statins in Animals and Humans: A Novel Mechanism of Statin Lactonization

Prueksaritanont, T., Subramanian, R., Fang, X., Ma, B., Qiu, Y., Lin, J. H., Pearson, P. G., & Baillie, T. A. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.5.505 · Cited by 344 · see citing works

The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy

Wilke, R. A., Ramsey, L. B., Johnson, S. G., Maxwell, W. D., McLeod, H. L., Voora, D., Krauss, R. M., Roden, D. M., Feng, Q., Cooper‐DeHoff, R. M., et al. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.57 · Cited by 332 · see citing works

Transporter Pharmacogenetics and Statin Toxicity

Niemi, M. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.197 · Cited by 329 · see citing works

Untitled work

(1997) · PubMed · Cited by 271 · see citing works

Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1

Nies, A. T., Niemi, M., Burk, O., Winter, S., Zanger, U. M., Stieger, B., Schwab, M. G., & Schaeffeler, E. (2013) · Genome Medicine · doi:10.1186/gm405 · Cited by 268 · see citing works

Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug.

Vickers, S., Duncan, C. A., Chen, I. W., Rosegay, A., & Duggan, D. E. (1990) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07595-6 · Cited by 246 · see citing works

Human skeletal muscle drug transporters determine local exposure and toxicity of statins

Knauer, M. J., Urquhart, B. L., Meyer zu Schwabedissen, H. E., Schwarz, U. I., Lemke, C. J., Leake, B. F., Kim, R. B., & Tirona, R. G. (2010) · Circulation Research · doi:10.1161/circresaha.109.203596 · Cited by 222 · see citing works

Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart

Grube, M., Köck, K., Oswald, S., Draber, K., Meissner, K., Eckel, L., Böhm, M., Felix, S. B., Vogelgesang, S., & Jedlitschky, G. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.09.010 · Cited by 215 · see citing works

Understanding the Critical Disposition Pathways of Statins to Assess Drug–Drug Interaction Risk During Drug Development: It's Not Just About OATP1B1

Elsby, R., Hilgendorf, C., & Fenner, K. (2012) · Clinical Pharmacology &amp; Therapeutics · doi:10.1038/clpt.2012.163 · Cited by 198 · see citing works

Different Effects of the <i>ABCG2</i> C.421C&gt;A SNP on the Pharmacokinetics of Fluvastatin, Pravastatin and Simvastatin

Keskitalo, J. E., Pasanen, M. K., Neuvonen, P. J., & Niemi, M. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.85 · Cited by 189 · see citing works

Clinical Pharmacokinetics and Practical Applications of Simvastatin

Mauro, V. F. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199324030-00002 · Cited by 187 · see citing works

The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6

Prueksaritanont, T., Ma, B., & Yu, N. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01833.x · Cited by 180 · see citing works

Power, Selection Bias and Predictive Performance of the Population Pharmacokinetic Covariate Model

Ribbing, J., & Jonsson, E. N. (2004) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1023/b:jopa.0000034404.86036.72 · Cited by 172 · see citing works

In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase.

Vickers, S., Duncan, C. A., Vyas, K. P., Kari, P. H., Arison, B. H., Prakash, S. R., Ramjit, H. G., Pitzenberger, S. M., Stokker, G. E., & Duggan, D. E. (1990) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08543-5 · Cited by 154 · see citing works

PPARA: A Novel Genetic Determinant of CYP3A4 In Vitro and In Vivo

Klein, K., Thomas, M., Winter, S., Nussler, A. K., Niemi, M., Schwab, M. G., & Zanger, U. M. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.336 · Cited by 153 · see citing works

ABCB1 Haplotypes Differentially Affect the Pharmacokinetics of the Acid and Lactone Forms of Simvastatin and Atorvastatin

Keskitalo, J. E., Kurkinen, K. J., Neuvonen, P. J., & Niemi, M. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.25 · Cited by 148 · see citing works

Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in The Rotterdam Study

Elens, L., Becker, M. L., Haufroid, V., Albert Hofman, D., Visser, L. E., Uitterlinden, A. G., Stricker, B. H. C., & van Schaik, R. H. N. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32834c6edb · Cited by 114 · see citing works

Effect of Polymorphic CYP3A5 Genotype on the Single‐Dose Simvastatin Pharmacokinetics in Healthy Subjects

Kim, K., Park, P., Lee, O., Kang, D., & Park, J. Y. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006295063 · Cited by 102 · see citing works

Use of Transporter Knockdown Caco-2 Cells to Investigate the In Vitro Efflux of Statin Drugs

Li, J., Volpe, D. A., Wang, Y., Zhang, W., Bode, C., Owen, A. J., & Hidalgo, I. J. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.038075 · Cited by 97 · see citing works

Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer

Zhou, Q. S., Sparreboom, A., Tan, E.-H., Cheung, Y., Lee, A., Poon, D. Y. H., Lee, E. J. D., & Chowbay, B. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02330.x · Cited by 94 · see citing works

Ethnic Variability in the Plasma Exposures of OATP1B1 Substrates Such as HMG-CoA Reductase Inhibitors: A Kinetic Consideration of Its Mechanism

Tomita, Y., Maeda, K., & Sugiyama, Y. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.221 · Cited by 88 · see citing works

Influence of Age and Gender on the Plasma Profiles of 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitory Activity Following Multiple Doses of Lovastatin and Simvastatin

Cheng, H., Rogers, J. D., Sweany, A. E., Dobrinska, M. R., Stein, E. A., Tate, A. C., Amin, R. D., & Quan, H. (1992) · Pharmaceutical Research · doi:10.1023/a:1015828811865 · Cited by 57 · see citing works

A Population Pharmacokinetic–Pharmacodynamic Model for Simvastatin that Predicts Low‐Density Lipoprotein‐Cholesterol Reduction in Patients with Primary Hyperlipidaemia

Kim, J., Ahn, B., Chae, H., Han, S., Doh, K., Choi, J., Jun, Y. K., Lee, Y. W., & Yim, D. (2011) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2011.00700.x · Cited by 43 · see citing works

Comparison of Model-Based Tests and Selection Strategies to Detect Genetic Polymorphisms Influencing Pharmacokinetic Parameters

Bertrand, J., Comets, E., & Mentré, F. (2008) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543400802369012 · Cited by 41 · see citing works

Interconversion Pharmacokinetics of Simvastatin and its Hydroxy Acid in Dogs: Effects of Gemfibrozil

Prueksaritanont, T., Qiu, Y., Mu, L., Michel, K., Brunner, J., Richards, K. M., & Lin, J. H. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-6037-2 · Cited by 35 · see citing works

Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm

Bertrand, J., Comets, E., Laffont, C. M., Chenel, M., & Mentré, F. (2009) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-009-9124-x · Cited by 34 · see citing works

Multiple single nucleotide polymorphism analysis using penalized regression in nonlinear mixed-effect pharmacokinetic models

Bertrand, J., & Balding, D. J. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32835dd22c · Cited by 20 · see citing works

Integration of high-throughput genotyping data into pharmacometric analyses using nonlinear mixed effects modeling

Lehr, T., Schaefer, H.-G., & Staab, A. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833b747f · Cited by 12 · see citing works

Membrane transporters in drug development and as determinants of precision medicine

Galetin, A., Brouwer, K. L. R., Tweedie, D., Yoshida, K. J., Sjöstedt, N., Aleksunes, L. M., Chu, X., Evers, R., Hafey, M. J., Lai, Y., et al. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00877-1 · Cited by 246 · see citing works

Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug‐Drug Interaction Evaluation: Perspectives From the International Transporter Consortium

Chu, X., Liao, M., Shen, H., Yoshida, K. J., Zur, A. A., Arya, V., Galetin, A., Giacomini, K. M., Hanna, I. H., Kusuhara, H., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1216 · Cited by 209 · see citing works

Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components

Turner, R. M., & Pirmohamed, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm9010022 · Cited by 201 · see citing works

An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins

Hirota, T., Fujita, Y., & Ieiri, I. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1801634 · Cited by 190 · see citing works

Drug–drug–gene interactions and adverse drug reactions

Malki, M. A., & Pearson, E. R. (2019) · The Pharmacogenomics Journal · doi:10.1038/s41397-019-0122-0 · Cited by 169 · see citing works

Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development

Lai, Y., Chu, X., Di, L., Gao, W., Guo, Y., Liu, X., Lu, C., Mao, J., Shen, H., Tang, H., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.03.009 · Cited by 169 · see citing works

How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion

Kell, D. B., & Oliver, S. G. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00231 · Cited by 155 · see citing works

Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium

Yee, S. W., Brackman, D. J., Ennis, E. A., Sugiyama, Y., Kamdem, L. K., Blanchard, R. L., Galetin, A., Zhang, L., & Giacomini, K. M. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1098 · Cited by 143 · see citing works

Breast Cancer Resistance Protein (ABCG2) in Clinical Pharmacokinetics and Drug Interactions: Practical Recommendations for Clinical Victim and Perpetrator Drug-Drug Interaction Study Design

Lee, C. A., O'Connor, M., Ritchie, T. K., Galetin, A., Cook, J., Ragueneau, I., Ellens, H. M., Feng, B., Taub, M. E., Paine, M. F., et al. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.062174 · Cited by 142 · see citing works

Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches

Guo, Y., Chu, X., Parrott, N. J., Brouwer, K. L. R., Hsu, V., Nagar, S., Matsson, P., Sharma, P. K., Snoeys, J., Sugiyama, Y., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1183 · Cited by 122 · see citing works

Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates

Saiz‐Rodríguez, M., Almenara, S., Navares‐Gómez, M., Ochoa, D., Román, M. C., Zubiaur, P., Koller, D., Santos, M., Mejía-Abril, G. P., Borobia, A. M., et al. (2020) · Biomedicines · doi:10.3390/biomedicines8040094 · Cited by 118 · see citing works

Parsing interindividual drug variability: an emerging role for systems pharmacology

Turner, R. M., Park, B. K., & Pirmohamed, M. (2015) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1302 · Cited by 91 · see citing works

Meta-Analysis of Expression of Hepatic Organic Anion–Transporting Polypeptide (OATP) Transporters in Cellular Systems Relative to Human Liver Tissue

Badée, J., Achour, B., Rostami‐Hodjegan, A., & Galetin, A. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.062034 · Cited by 91 · see citing works

Pharmacogenomics of statins: understanding susceptibility to adverse effects

Kitzmiller, J., Mikulik, E., Dauki, A. M., Mukherjee, C., & Luzum, J. A. (2016) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s86013 · Cited by 92 · see citing works

Genetics, Dyslipidemia, and Cardiovascular Disease: New Insights

Stein, R., Ferrari, F., & Scolari, F. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1161-5 · Cited by 83 · see citing works

CYP3A4∗22 Genotyping in Clinical Practice: Ready for Implementation?

Mulder, T. A. M., van Eerden, R. A. G., de With, M., Elens, L., Hesselink, D. A., Matić, M., Bins, S., Mathijssen, R. H. J., & van Schaik, R. H. N. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.711943 · Cited by 82 · see citing works

ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?

Bruckmueller, H., & Cascorbi, I. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1876661 · Cited by 77 · see citing works

Utilization of Physiologically Based Pharmacokinetic Modeling in Clinical Pharmacology and Therapeutics: an Overview

Perry, C., Davis, G., Conner, T. M., & Zhang, T. (2020) · Current Pharmacology Reports · doi:10.1007/s40495-020-00212-x · Cited by 75 · see citing works

Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach

Tsamandouras, N., Dickinson, G., Guo, Y., Hall, S., Rostami-Hodjegan, A., Galetin, A., & Aarons, L. (2015) · Pharmaceutical Research · doi:10.1007/s11095-014-1581-2 · Cited by 64 · see citing works

Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid

Choi, H. Y., Bae, K.-S., Cho, S.-H., Ghim, J.-L., Choe, S., Jung, J. A., Jin, S.-J., Kim, H.-S., & Lim, H.-S. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000176 · Cited by 49 · see citing works

Patients experiencing statin-induced myalgia exhibit a unique program of skeletal muscle gene expression following statin re-challenge

Elam, M. B., Majumdar, G., Mozhui, K., Gerling, I., VERA, S. R., Fish-Trotter, H. L., Williams, R. W., Childress, R. D., & Raghow, R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181308 · Cited by 50 · see citing works

Activating and Inhibitory Functions of WNT/β-Catenin in the Induction of Cytochromes P450 by Nuclear Receptors in HepaRG Cells

Thomas, M., Bayha, C., Vetter, S., Hofmann, U., Schwarz, M., Zanger, U. M., & Braeuning, A. (2015) · Molecular Pharmacology · doi:10.1124/mol.114.097402 · Cited by 39 · see citing works

Physiologically Based Precision Dosing Approach for Drug‐Drug‐Gene Interactions: A Simvastatin Network Analysis

Wojtyniak, J., Selzer, D., Schwab, M., & Lehr, T. (2021) · Clinical Pharmacology &amp; Therapeutics · doi:10.1002/cpt.2111 · Cited by 38 · see citing works

Design and Measurement of Drug Tissue Concentration Asymmetry and Tissue Exposure-Effect (Tissue PK-PD) Evaluation

Zang, R., Barth, A., Wong, H., Mařı́k, J., Shen, J., Lade, J. M., Grove, K. J., Durk, M. R., Parrott, N. J., Rudewicz, P. J., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00502 · Cited by 37 · see citing works

PBPK Model of Coproporphyrin I: Evaluation of the Impact of SLCO1B1 Genotype, Ethnicity, and Sex on its Inter‐Individual Variability

Takita, H., Barnett, S., Zhang, Y., Ménochet, K., Shen, H., Ogungbenro, K., & Galetin, A. (2020) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12582 · Cited by 36 · see citing works

Utilization of Data Below the Analytical Limit of Quantitation in Pharmacokinetic Analysis and Modeling: Promoting Interdisciplinary Debate

Hecht, M., Veigure, R., Couchman, L., S Barker, C. I., Standing, J. F., Takkis, K., Evard, H., Johnston, A., Herodes, K., Leito, I., et al. (2018) · Bioanalysis · doi:10.4155/bio-2018-0078 · Cited by 34 · see citing works

Genetic and Clinical Factors Are Associated With Statin‐Related Myotoxicity of Moderate Severity: A Case–Control Study

Bakar, N. S., Neely, D., Avery, P. J., Brown, C., Daly, A. K., & Kamali, F. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.887 · Cited by 32 · see citing works

Individual and Combined Associations of Genetic Variants in CYP3A4, CYP3A5, and SLCO1B1 With Simvastatin and Simvastatin Acid Plasma Concentrations

Luzum, J. A., Theusch, E., Taylor, K. D., Wang, A., Sadée, W., Binkley, P. F., Krauss, R. M., Medina, M. W., & Kitzmiller, J. P. (2015) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000246 · Cited by 32 · see citing works

When the same treatment has different response: The role of pharmacogenomics in statin therapy

Zheng, E., Madura, P., Grandos, J., Broncel, M., Pawlos, A., Woźniak, E., & Gorzelak‐Pabiś, P. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115966 · Cited by 27 · see citing works

In vitro/in silicoapproach in the development of simvastatin-loaded self-microemulsifying drug delivery systems

Ćetković, Z., Cvijić, S., & Vasiljević, D. (2017) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2017.1414835 · Cited by 27 · see citing works

Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments

Berinstein, E. M., & Levy, A. P. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1363887 · Cited by 27 · see citing works

Hepatic solute carrier transporters and drug therapy: Regulation of expression and impact of genetic variation.

Nies, A., Schaeffeler, E., & Schwab, M. (2022) · Pharmacology and Therapeutics · doi:10.1016/j.pharmthera.2022.108268 · Cited by 21 · see citing works

Modelling of atorvastatin pharmacokinetics and the identification of the effect of a BCRP polymorphism in the Japanese population

Tsamandouras, N., Guo, Y., Wendling, T., Hall, S. D., Galetin, A., & Aarons, L. J. (2016) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000252 · Cited by 22 · see citing works

Does the choice of applied physiologically‐based pharmacokinetics platform matter? A case study on simvastatin disposition and drug–drug interaction

Prieto Garcia, L., Lundahl, A., Ahlström, C., Vildhede, A., Lennernäs, H., & Sjögren, E. (2022) · CPT: Pharmacometrics &amp; Systems Pharmacology · doi:10.1002/psp4.12837 · Cited by 21 · see citing works

Dealing With Variable Drug Exposure Due to Variable Hepatic Metabolism: A Proof‐of‐Concept Application of Liquid Biopsy in Renal Impairment

Rostami‐Hodjegan, A., Al‐Majdoub, Z. M., von Grabowiecki, Y., Yee, K. L., Sahoo, S., Breitwieser, W., Galetin, A., Gibson, C. R., & Achour, B. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3291 · Cited by 20 · see citing works

Pharmacogenomics of Cardiovascular Drugs for Atherothrombotic, Thromboembolic and Atherosclerotic Risk

Mauriello, A., Ascrizzi, A., Molinari, R., Falco, L., Caturano, A., D’Andrea, A., & Russo, V. (2023) · Genes · doi:10.3390/genes14112057 · Cited by 18 · see citing works

Genomic and Precision Medicine Approaches in Atherosclerotic Cardiovascular Disease: From Risk Prediction to Therapy—A Review

Mitsis, A., Khattab, E., Kyriakou, M., Sokratous, S., Sakellaropoulos, S., Tzikas, S., Kadoglou, N. P. E., & Kassimis, G. (2025) · Biomedicines · doi:10.3390/biomedicines13071723 · Cited by 16 · see citing works

Population Pharmacokinetics of Methylphenidate in Healthy Adults Emphasizing Novel and Known Effects of Several Carboxylesterase 1 (CES1) Variants

Lyauk, Y. K., Stage, C., Bergmann, T. K., Ferrero‐Miliani, L., Bjerre, D., Thomsen, R., Dalhoff, K., Rasmussen, H., & Jűrgens, G. (2016) · Clinical and Translational Science · doi:10.1111/cts.12423 · Cited by 15 · see citing works

Chronopharmacology of simvastatin on hyperlipidaemia in high‐fat diet‐fed obese mice

Li, H., Rabearivony, A., Zhang, W., Chen, S., An, X., & Liu, C. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15709 · Cited by 14 · see citing works

Effects of CYP3A4*22 polymorphism on trough concentration of tacrolimus in kidney transplantation: a systematic review and meta-analysis

Kim, J. S., Shim, S.-Y., Yee, J., Choi, K. H., & Gwak, H. S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1201083 · Cited by 13 · see citing works

ZNF542P is a pseudogene associated with LDL response to simvastatin treatment

Kim, K., Theusch, E., Kuang, Y., Dosé, A. C., Mitchel, K., Cubitt, C. C., Chen, Y. I., Krauss, R. M., & Medina, M. W. (2018) · Scientific Reports · doi:10.1038/s41598-018-30859-y · Cited by 12 · see citing works

Dietary supplements, cytochrome metabolism, and pharmacogenetic considerations

Matura, J. M., Shea, L. A., & Bankes, V. A. (2021) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-021-02828-4 · Cited by 12 · see citing works

Genotype, Ethnicity, and Drug–Drug Interaction Modeling as Means of Verifying Transporter Biomarker PBPK Model: The Coproporphyrin‐I Story

Ujihira, Y., Tan, S. P. F., Scotcher, D., & Galetin, A. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70008 · Cited by 10 · see citing works

Assessment of Transporter Polymorphisms as a Factor in a BCRP Drug Interaction Study With Lanabecestat

Willis, B. A., Andersen, S. W., Ayan‐Oshodi, M., James, D. E., Liffick, E., Hillgren, K. M., Guo, Y., & Monk, S. A. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1500 · Cited by 10 · see citing works

Pharmacogenetics in Cardiovascular Medicine

Weeke, P. E. (2018) · Advances in pharmacology · doi:10.1016/bs.apha.2018.04.002 · Cited by 10 · see citing works

A population pharmacokinetic model for simvastatin and its metabolites in children and adolescents

Ogungbenro, K., Wagner, J. B., Abdel‐Rahman, S. M., Leeder, J. S., & Galetin, A. (2019) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-019-02697-y · Cited by 8 · see citing works

Single Nucleotide Polymorphisms in Cellular Drug Transporters Are Associated with Intolerance to Antiretroviral Therapy in Brazilian HIV-1 Positive Individuals

Arruda, M. B., Campagnari, F., de Almeida, T. B., Couto-Fernandez, J. C., Tanuri, A., & Cardoso, C. C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163170 · Cited by 8 · see citing works

Mapping SLCO1B1 Genetic Variation for Global Precision Medicine in Understudied Regions in Africa: A Focus on Zulu and Cape Admixed Populations

Hoosain, N., Pearce, B., Jacobs, C., & Benjeddou, M. (2016) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2016.0115 · Cited by 6 · see citing works

Drug-drug interactions

Galetin, A., Zhang, L., Rodrigues, A. D., & Huang, S. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819869-8.00013-6 · Cited by 6 · see citing works

Impacts of Pharmacokinetic Gene Polymorphisms on Steady‐State Plasma Concentrations of Simvastatin in Thai Population

Tipnoppanon, S., Udomnilobol, U., Siwamogsatham, S., Vorasettakarnkij, Y., Sukasem, C., Prueksaritanont, T., Chariyavilaskul, P., Yodsurang, V., Srimatimanon, T., Chamnanphon, M., et al. (2025) · Clinical and Translational Science · doi:10.1111/cts.70225 · Cited by 5 · see citing works

Relative bioavailability enhancement of simvastatin via dry emulsion systems: Comparison of spray drying and fluid bed layering technology

Pohlen, M., Zdovc, J. A., Trontelj, J., Mravljak, J., Matjaž, M. G., Grabnar, I., Snoj, T., & Dreu, R. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.12.004 · Cited by 5 · see citing works

Genetic Polymorphisms in SLCO2B1 and ABCC1 Conjointly Modulate Atorvastatin Intracellular Accumulation in HEK293 Recombinant Cell Lines

Hoste, E., Paquot, A., Panin, N., Horion, S., Hamdaoui, H. E., Muccioli, G. G., Haufroid, V., & Elens, L. (2022) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001043 · Cited by 5 · see citing works

New Drug Development and Clinical Trial Design by Applying Genomic Information Management

Ko, Y. K., & Gim, J. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081539 · Cited by 5 · see citing works

Using Prior Knowledge on Systems Through PBPK to Gain Further Insight into Routine Clinical Data on Trough Concentrations: The Case of Tacrolimus in Chronic Kidney Disease

El‐Khateeb, E., Chinnadurai, R., Al-Qassabi, J., Scotcher, D., Darwich, A. S., Kalra, P. A., & Rostami‐Hodjegan, A. (2023) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001108 · Cited by 4 · see citing works

Pharmacokinetics and lipid-lowering efficacy affected by polymorphisms in genetic variability in statin therapy

Rajput, M., Rizvi, S., Pratap, P. D., Raza, S. T., Siddiqi, Z., & Khare, V. (2025) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-025-00787-4 · Cited by 3 · see citing works

CYP3A4⁎22 gene polymorphism and risk of ischemic stroke in south Iran population: A case control study

Divsalar, B., Kalantari, T., Mohebbi, S., Bahmanimehr, A., Dehbidi, G. R., & Borhani‐Haghighi, A. (2021) · Meta Gene · doi:10.1016/j.mgene.2021.100932 · Cited by 3 · see citing works

Pharmacogenomics of Lipid-Lowering Agents: the Impact on Efficacy and Safety

Shatnawi, A. A., Kamran, Z., & Al–Share, Q. Y. (2022) · Personalized Medicine · doi:10.2217/pme-2022-0041 · Cited by 3 · see citing works

PPARA gene and phenprocoumon

Botton, M. R., Bandinelli, E., Leiria, T. L. L., Rohde, L. E. P., & Hutz, M. H. (2014) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000109 · Cited by 3 · see citing works

Evaluating genotype–treatment interactions for high-risk medications in British general practice: a retrospective cohort study using UK Biobank

Mokbel, K., Weedon, M. N., DANIELS, R., Moye, V., & Jackson, L. M. (2025) · British Journal of General Practice · doi:10.3399/bjgp.2024.0806 · Cited by 2 · see citing works

Pharmacogenomics of Atherosclerotic Plaque: Pathophysiological Background and Therapeutic Perspectives

Mauriello, A., Falco, A. D., Correra, A., D’Andrea, A., Giallauria, F., Giordano, A., & Russo, V. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01414-2 · Cited by 2 · see citing works

Redefining Statin Dosage Post‐Gastric Bypass: Insights from a Population Pharmacokinetics–Pharmacodynamics Link Approach

Costa, A., Medeiros, J. I. M., Kang, W.-H., Yamamoto, P. A., de Gaitani, C. M., Vasconcelos, M. E. D., da Silva, R. M., Kemp, R., Sankarankutty, A. K., Salgado, W., et al. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.6110 · Cited by 2 · see citing works

Association between the cumulative defined daily dose of statins and ischemic stroke recurrence: a cohort study

Han, Y., Bian, Z., Gu, H., Guo, D., Li, R., Liu, L., Wang, D., & Peng, Y. (2026) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2026.111873 · Cited by 1 · see citing works

Major Genetic Drivers of Statin Treatment Response in African Populations and Pharmacogenetics of Dyslipidemia Through a One Health Lens

Lusiki, Z., Blom, D. J., Soko, N. D., Malema, S., Jones, E. S. W., Rayner, B. L., Blackburn, J. M., Sinxadi, P., Dandara, M. T. L., & Dandara, C. (2023) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2023.0122 · Cited by 1 · see citing works

Pharmacokinetics and Bioequivalence of Fixed‐Dose Combination of Simvastatin and Ezetimibe Tablets: A Randomized, Crossover, Open‐Label Study in Healthy Volunteers

Leong, C. W., Yee, K. M., Rani, T. A., Lau, K. J., Ahmad, S., Amran, A., Hassan, F. W. M., & Kumar, N. (2024) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1411 · Cited by 1 · see citing works

Comparative analysis of the nuclear receptors CAR, PXR and PPARα in the regulation of hepatic energy homeostasis and xenobiotic metabolism

Kandel, B. A. (2014) · OPUS Publication Server of the University of Stuttgart (University of Stuttgart) · doi:10.18419/opus-8263

Simvastatin therapy in different subtypes of hypercholesterolemia – a physiologically based modelling approachPreprint

Bartsch, F., Grzegorzewski, J., Pujol, H. L., Tautenhahn, H., & König, M. (2023) · medRxiv · doi:10.1101/2023.02.01.23285358

The Construction of CRISPR-Cas9 System Targeting Vector for CYP3A4 Gene in Hepatic Cell Lines

Hatta, F. H. M., Aziz, F. N. A., Shafiq‐ur‐Rehman, & Othman, A. A. (2024) · Journal of Advanced Research in Applied Sciences and Engineering Technology · doi:10.37934/araset.43.2.178188

Verification of a Physiologically-based Pharmacokinetic Model for Predicting CYP3A4-mediated Simvastatin and Simvastatin Acid Drug-drug Interactions

Morse, B. L., Han, B., Alberts, J. J., Posada, M. M., Dickinson, G. L., & Hall, S. D. (2026) · The AAPS Journal · doi:10.1208/s12248-026-01299-8

Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid

Choi, H. Y., Bae, K.-S., Cho, S.-H., Ghim, J.-L., Choe, S., Jung, J. A., Jin, S.-J., Kim, H.-S., & Lim, H.-S. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000176 · Cited by 49 · see citing works

Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach

Tsamandouras, N., Dickinson, G., Guo, Y., Hall, S., Rostami-Hodjegan, A., Galetin, A., & Aarons, L. (2015) · Pharmaceutical Research · doi:10.1007/s11095-014-1581-2 · Cited by 64 · see citing works

Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms

Zhou, Q., Ruan, Z., Jiang, B., Yuan, H., & Zeng, S. (2013) · Die Pharmazie · doi:10.31083/ph.2013.2676 · Cited by 23 · see citing works

Impacts of Pharmacokinetic Gene Polymorphisms on Steady‐State Plasma Concentrations of Simvastatin in Thai Population

Tipnoppanon, S., Udomnilobol, U., Siwamogsatham, S., Vorasettakarnkij, Y., Sukasem, C., Prueksaritanont, T., Chariyavilaskul, P., Yodsurang, V., Srimatimanon, T., Chamnanphon, M., et al. (2025) · Clinical and Translational Science · doi:10.1111/cts.70225 · Cited by 5 · see citing works

Genomewide Association Study of Simvastatin Pharmacokinetics

Mykkänen, A. J. H., Taskinen, S., Neuvonen, M., Paile‐Hyvärinen, M., Tarkiainen, E. K., Lilius, T. O., Tapaninen, T., Backman, J. T., Tornio, A., & Niemi, M. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2674 · Cited by 46 · see citing works